The technology was developed in the laboratory of Andrew Lever at the University of Cambridge. Following the acquisition of the Cell Genesys’s lentiviral patent portfolio in 2007 by GBP Capital, the majority shareholder in Lentigen, this license is said to further consolidate Lentigen’s intellectual property position.
Boro Dropulic, founder, president and chief scientific officer of Lentigen, said: “The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies.”